Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Malignant hyperthermia. The ugly].

H Rüffert1, M Wehner, C Deutrich

  • 1Klinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum Leipzig AöR, Liebigstr. 20, 04103 Leipzig. henrik.rueffert@medizin.uni-leipzig.de

Der Anaesthesist
|June 15, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Comments on the guidelines of the European Malignant Hyperthermia Group on the availability of dantrolene for the management of malignant hyperthermia crises].

Der Anaesthesist·2020
Same author

A multiyear cross-sectional study of U.S. national prescribing patterns of first-generation sedating antihistamines in older adults with skin disease.

The British journal of dermatology·2019
Same author

Facebook advertising for cancer prevention: a pilot study.

The British journal of dermatology·2019
Same author

[Correction to: Telephone enquiries on the topic of malignant hyperthermia].

Der Anaesthesist·2018
Same author

Determination of the thermal properties of leaves by non-invasive contact‑free laser probing.

Journal of biotechnology·2015
Same author

[Telephone enquiries on the topic of malignant hyperthermia: Evaluation of the content and subsequent diagnostic results at the MH Center Leipzig].

Der Anaesthesist·2015
Same journal

[Promoting young academics in anesthesiology: factors for an attractive internship].

Der Anaesthesist·2022
Same journal

[Respiratory support in COVID-19: all in due time!]

Der Anaesthesist·2022
Same journal

[Noninvasive respiratory support and invasive ventilation in COVID‑19 : Where do we stand today?]

Der Anaesthesist·2022
Same journal

[Management of acutely decompensated liver cirrhosis in emergency and critical care medicine].

Der Anaesthesist·2022
Same journal

[Anesthesia in patients with acute porphyria].

Der Anaesthesist·2022
Same journal

[Quality and safe anesthesia for all children : That is their right!]

Der Anaesthesist·2022
See all related articles

Malignant hyperthermia (MH) is a rare anesthesia complication caused by muscle cell defects. Early diagnosis and treatment are crucial for managing this life-threatening condition, especially outside hospital settings.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Genetics

Context:

  • Malignant hyperthermia (MH) is a severe, potentially fatal reaction to certain anesthetic agents.
  • It is primarily linked to genetic defects in the ryanodine receptor subtype 1.
  • Other conditions like myotonias and muscular dystrophies can also trigger MH-like symptoms.

Purpose:

  • To define malignant hyperthermia (MH) as a clinical syndrome.
  • To elucidate the underlying pathophysiology involving calcium release in muscle cells.
  • To highlight diagnostic and therapeutic considerations in perioperative care.

Summary:

  • MH presents as a spectrum of severity, from mild to life-threatening crises, triggered by specific substances or mechanisms.
  • The core issue is excessive calcium release into skeletal muscle cytoplasm, often due to genetic defects.

Related Experiment Videos

  • While perioperative MH is treatable with current knowledge, atypical presentations and non-anesthetic triggers pose diagnostic challenges.

    • Impact:

    • Improved understanding of MH pathophysiology aids in accurate diagnosis and timely intervention.
    • Awareness of atypical triggers and non-hospital settings is vital for preventing misdiagnosis.
    • Distinguishing MH from similar syndromes like neuroleptic malignant syndrome and serotonin syndrome is critical for patient outcomes.